The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Convergence 2020: Studies in Rheumatoid Arthritis

ACR Convergence 2020: Studies in Rheumatoid Arthritis

November 8, 2020 • By Keri Losavio

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—Moderated by Bill St.Clair, MD, MACR, an ACR past president and a professor of medicine and immunology at Duke University Medical Center, Durham, N.C., an abstract session on Friday, Nov. 6, focused on the diagnosis, manifestations and outcomes of rheumatoid arthritis (RA), with a focus on interstitial lung disease.

You Might Also Like
  • ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
  • Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
  • Pain in RA and OA: ACR Convergence 2020 Preview
Explore This Issue
December 2020
Also By This Author
  • Prior Authorization Reform Achieves Some Success

RA with ILD

Jeffrey Sparks, MD, MSc, an assistant professor of medicine at Brigham and Women’s Hospital, Boston, presented the results of two studies: “Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study” (abstract 0489) and “Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease” (abstract 0490).1,2

Dr. Sparks

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations, and its prevalence may be increasing. According to Dr. Sparks, “RA-ILD is associated with a median overall survival of only three to eight years.” Thus, Dr. Sparks and his colleagues investigated the prevalence, incidence and cause-specific mortality of RA-ILD using a recently validated claims-based algorithm in a retrospective cohort study using U.S. claims data from Medicare (2008–17).

The researchers concluded that RA-ILD was present or developed in nearly 5% of “older” patients with RA (Note: The abstract did not define older; however, the study population comprised Medicare patients, so the patients were 65 or older.) RA-ILD was associated with excess total mortality that was not explained by measured factors. They confirmed the association of male sex and smoking with incident RA-ILD. They further noted that biologic disease-modifying anti-rheumatic drug (DMARD) use and glucocorticoid use were associated with incident RA-ILD. Patients with RA-ILD had a strongly associated increased risk of respiratory mortality than patients with RA without ILD.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the second study presentation, Dr. Sparks said the researchers investigated fine specificity anti-citrullinated protein antibodies (ACPA) and the subsequent risk of RA-ILD. They were able to identify several fine specificity ACPA associated with subsequent risk of RA-ILD that may inform pathogenesis. In particular, their study showed that “autoimmunity to a specific citrullinated epitope of filaggrin was associated with RA-ILD across all isotypes investigated and is potentially a novel predictive biomarker for RA-ILD. … These results suggest that fine specificity ACPA biomarkers may have utility in RA-ILD prediction.”

RA & Pulmonary Function

Ms. Prisco

Lauren Prisco, BA, the clinical research coordinator at Brigham and Women’s Hospital, presented the results of a study on the relationship between RA and pulmonary function (abstract 0491).3

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR Convergence 2020, ACR Convergence 2020 – RAIssue: December 2020

You Might Also Like:
  • ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis
  • Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020
  • Pain in RA and OA: ACR Convergence 2020 Preview
  • Racial Disparity in RA & OA: ACR Convergence 2020 Preview

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.